The Effectiveness of Voriconazole in Therapy of Candida glabrata’s Biofilms Oral Infections and Its Influence on the Matrix Composition and Gene Expression
- 324 Downloads
Candida glabrata is one of most prevalent yeast in fungal infections, especially in immunocompromised patients. Its azole resistance results in a low therapeutic response, particularly when associated with biofilms. The main goal of this work was to study the effectiveness of voriconazole (Vcz) against C. glabrata biofilms oral pathologies, as esophageal or oropharyngeal candidiasis. Antifungal susceptibilities were determined in pre-formed 24-h-biofilms and ERG genes expression was determined by qRT-PCR. Protein quantification was performed using BCA® Kit, carbohydrate was estimated according to the Dubois assay and β-1,3 glucans concentration were determined using Glucatell® kit. Finally, ergosterol, Vcz, and fluconazole (Flu) concentrations within the biofilm matrices were determined by RP-HPLC. Results showed that C. glabrata biofilms were more susceptible to Vcz than to Flu and that ERG genes expression evidenced an overexpression of the three ERG genes in the presence of both azoles. The matrix content presented a remarked decrease in proteins and an increase in carbohydrates, namely β-1,3 glucans. Ergosterol was successfully detected and quantified in the biofilm matrices, with no differences in all the considered conditions. Vcz demonstrated better diffusion through the biofilms and better cell penetration capacities, than Flu, indicating that the structure of the drug molecule fully influences its dissemination through the biofilm matrices. This work showed that Vcz is notably more effective than Flu for the treatment of resistant C. glabrata oral biofilms, which demonstrates a clinical relevance in its future use for the treatment of oropharyngeal/esophageal candidiasis caused by this species.
KeywordsCandidiasis Antifungal Resistance Matrix Voriconazole Candida
This work was supported by the Programa Operacional, Fatores de competitividade—COMPETE and by national funds through FCT—Fundação para a Ciência e a Tecnologia on the scope of the projects FCT [PTDC/SAU-MIC/119069/2010], [RECI/EBB-EBI/0179/2012], [PEst-OE/EQB/LA0023/2013] and Célia F. Rodrigues’ [SFRH/BD/93078/2013] PhD Grant. The authors thank the Project “BioHealth—Biotechnology and Bioengineering approaches to improve health quality”, Ref. NORTE-07-0124-FEDER-000027, co-funded by the Programa Operacional Regional do Norte (ON.2—O Novo Norte), QREN, FEDER. The authors would like to acknowledge Pfizer®, S.A. for the kindly donation of Voriconazole and Fluconazole.
Compliance with Ethical Standards
Conflict of interest
All the authors declare that there is no financial/personal interest or belief that could affect their objectivity.
- 8.Marti CJ, Alvarez RM. Herpes simplex esophagitis associated to Candida albicans in an immunocompetent host. An Med Interna. 2004;21:312.Google Scholar
- 28.Ibrahim A, Eldin B, Ibrahim A, Eldin B, Shalaby A. Determination of voriconazole and its degradation products in pharmaceutical formulations using high performance liquid chromatography with ultra–violet detection. Eurasian J Anal Chem. 2010;5:254–64.Google Scholar
- 29.Sadasivudu P, Shastri N, Sadanandam M. Development and validation of RP-HPLC and UV methods of analysis for fluconazole in pharmaceutical solid dosage forms. Int J ChemTech Res. 2009;1:1131–6.Google Scholar
- 39.European Committee on Antimicrobial Susceptibility Testing – Antifungal agents, Breakpoint tables for interpretation of MICs, Version 8.0, valid from 2015-11-16. http://www.eucast.org/clinical_breakpoints/
- 40.Kowalsdy S, Dixon D. Fluconazole: a new antifungal agent. Clin Pharm. 1990;10:179–90.Google Scholar
- 41.Janssen P, Vanden J, Bossche H. Mode of action cytochrome P450 monooxygenase inhibitors. Focus on azole derivates. Arch Pharm Chem Sci. 1987;15:23–40.Google Scholar
- 45.Grandesso S, Sapino B, Mazzuccato S, Solinas M, Bedin M, D’Angelo M, et al. Study on in vitro susceptibility of Candida spp. isolated from blood culture. Infect Med. 2012;20:25–30.Google Scholar
- 53.Tzu Shan N, Desa MNM, Sandai D, Chong PP, Than LTL. Growth, biofilm formation, antifungal susceptibility and oxidative stress resistance of Candida glabrata are affected by different glucose concentrations. Infect Genet Evol Elsevier B.V. 2015;40:331–8.Google Scholar